Thomas Kelly compensation by year
Xenon Pharmaceuticals Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $114,545 |
| Bonus | $0 |
| Stock awards | $1,257,000 |
| Option awards | $5,809,602 |
| Non-equity incentive | $51,545 |
| Pension and deferred compensation | $0 |
| All other | $5,972 |
| Total | $7,238,664 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Xenon Pharmaceuticals Inc. DEF 14A filed April 22, 2026, accession 0001193125-26-170320, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Xenon Pharmaceuticals Inc. filed document, accession 0001193125-26-170320. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 30,000 | $1,344,600 | — |
| Option | 225,000 | — | $41.90 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Xenon Pharmaceuticals Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Xenon Pharmaceuticals discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $540,000 | $0 | $71,778 | $611,778 |
| Change in control and involuntary termination | $540,000 | $2,001,600 | $71,778 | $2,856,378 |
| Change in control, no termination | $0 | $0 | $0 | $0 |
Per the Potential Payments Upon Termination or Change in Control table in Xenon Pharmaceuticals Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Xenon Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Ian Mortimer | President and Chief Executive Officer | $9,221,712 |
| Thomas Kelly · this page | Chief Financial Officer | $7,238,664 |
| Darren Cline | Chief Commercial Officer | $4,048,214 |
| Christopher Kenney | Chief Medical Officer | $3,145,290 |
| Andrea DiFabio | Chief Legal Officer and Corporate Secretary | $3,062,790 |
| Sherry Aulin | Former Chief Financial Officer | $356,453 |
The full Xenon Pharmaceuticals compensation record
free company briefThis page is one person within Xenon Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Xenon Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Xenon Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Xenon Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order XENE
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.